Useful Measurement of Glucose Variability by Flash Glucose Monitoring (FGM) with the Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Ebe K; Bando Hiroshi; Muneta T; Bando Masahiro; Yonei Y

タイトル	Useful Measurement of Glucose Variability by Flash Glucose Monitoring (FGM) with the Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
作成者	Ebe, K Bando, Hiroshi Muneta, T Bando, Masahiro Yonei, Y
権利情報	© 2020 Ebe K, Bando H, Muneta T, Bando M, Yonei Y. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
主題	Other Low Carbohydrate Diet Other Continuous Glucose Monitoring Other FreeStyle Libre Pro Other Flash Glucose Monitoring Other Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Other Japan LCD Promotion Association (JLCDPA)
内容注記	Other Diabetes has been a crucial medical and social problem worldwide. For adequate nutritional therapy, there have been discussions concerning Calorie Restriction (CR) and Low Carbohydrate Diet (LCD). We have investigated glucose variability of diabetic patients applying CR, LCD, continuous glucose monitoring (CGM) and applied FreeStyle Libre which is flash glucose monitoring (FGM). The patient is a 40-year-old female with type 2 diabetes mellitus (T2DM), who showed BMI 20.7, postprandial blood glucose 257 mg/dL. HbA1c 12.1%, Glycoalbumin 31.6% (11.6-16.4), serum C-peptide 2.0 ng/ml and unremarkable data of liver function, renal, lipids. She was provided the intervention of three stages, which are i) CR with 60% carbohydrate in Day 1-2, ii) LCD meal with 12% carbohydrate in Day 3-5; iii) LCD + Sodium-glucose cotransporter 2 (SGLT2) inhibitor (Ipragliflozin L-Proline 50mg) in Day 6-12. The glucose profile was measured by FreeStyle Libre Pro (Abbott) for 14 days. The daily profile of blood glucose was abruptly decreased on Day 6. Time percentage of satisfactory blood glucose 70-180 mg/dL (/24h) was 0%, 0%, 2%, 14%, 0%, 54%, 100% in Day 1-7, respectively. These results suppose the acute clinical efficacy of SGLT2 inhibitor, and this report would become a reference for future diabetic practice and research.
出版者	Asploro
日付	Issued2020-01-06
言語	eng
資源タイプ	journal article
出版タイプ	VoR
資源識別子	URI http://repo.lib.tokushima-u.ac.jp/114793
関連	isIdenticalTo DOI https://doi.org/10.36502/2020/droa.6154
収録誌情報	Diabetes Research : Open Access 巻2 号S1 開始ページ1 終了ページ8
ファイル	http://repo.lib.tokushima-u.ac.jp/files/public/11/114793/2020052610071298342/droa_2_S1_1.pdf (application/pdf)
コンテンツ更新日時	2023-06-26